Alfonso-Pierola A, Martinez-Cuadron D, Rodriguez-Veiga R, Gil C, Martinez-Sanchez P, Bernal T, Benavente C, Romero-Riquelme MA, Serrano-Lopez J, Bergua JM, Garcia-Boyero R, Tormo M, Herrera P, Sossa-Melo CL, Perez-Simon JA, Rodriguez-Medina C, Bass-Maturana MF, Lopez-Lorenzo JL, Algarra-Algarra L, Vidriales-Vicente B, Perez-Encinas M, Barrios-Garcia M, Vives S, Sayas-Lloris MJ, Capurro M, Hidalgo S, Olave M, Cuervo-Lozada D, Lavilla-Rubira E, Casado F, Mena-Duran A, Valero-Nunez M, Casado-Calderon S, Balerdi A, Torres V, Fernandez R, Noriega V, Stevenazzi M, Labrador J, Leon-Maldonado P, de Rueda-Ciller B, Arce-Fernandez O, Amigo ML, Raposo-Puglia JA, Sole M, Boluda B, Ayala R, Barragan E, Montesinos P; PETHEMA Group. Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry. Leukemia. 2025 Nov;39(11):2686-2696. doi: 10.1038/s41375-025-02744-x. Epub 2025 Sep 1. PubMed PMID: 40890512; PubMed Central PMCID: PMC12589098.
AÑO: 2025; IF: 13.4